Biotechs make inroads to precision medicine, solving long-standing problems

Recent drug approvals show small and medium-sized players are becoming increasingly successful at navigating the obstacles to get precision therapies across the FDA finish line. The data suggest pharma’s dominance in the area is not as absolute as it once was.

Biomarker-defined patient populations can be right-sized opportunities for biotechs, even small ones, but clinical development of precision medicines brings complexity. With the right indication and strategy, however, biotechs are helping drive the wave of precision medicine in oncology. Small and mid-sized players have even received a handful of approvals outside cancer...